PUBLISHER: FirstWord Group | PRODUCT CODE: 1564674
PUBLISHER: FirstWord Group | PRODUCT CODE: 1564674
Non-Small Cell Lung Cancer - Targeted Therapies - KOL Insight
This report provides an in-depth analysis of the evolving landscape of targeted therapies for non-small cell lung cancer (NSCLC), based on insights from 12 key opinion leaders (KOLs) from North America and Europe. Key findings include the redefinition of Tagrisso's use in EGFR-mutated NSCLC through multiple Phase III studies, the expansion of Rybrevant's application beyond niche populations despite its challenging toxicity profile, and the limited but growing uptake of Enhertu in HER2 mutant NSCLC. The report offers a comprehensive review of current and future treatment pathways, addressing unmet needs and emerging trends in the NSCLC market.
Key brands covered in this report:
|
|
Key questions answered:
- How is the use of Tagrisso expected to evolve in the treatment of EGFRm NSCLC?
- What are the potential therapies for second-line treatment in patients resistant to third-generation EGFR-TKIs?
- How will Rybrevant's use change with new data and regulatory approvals?
- What impact will the approval of Enhertu for HER2-mutant NSCLC have on its uptake?
- Can pipeline HER2-targeting therapies like zongertinib offer competitive advantages over existing treatments?
- How will new data from studies like CROWN and ALINA affect treatment practices for ALK-positive NSCLC?
- What are the prospects for new targeted therapies for KRAS, MET, RET, ROS1, and BRAF mutations in NSCLC?
- How confident are KOLs in the impact of ADCs currently in development on the treatment paradigm?
Companies:
AbbVie, Amgen, Novartis, Lilly, Roche, AstraZeneca, Pfizer, Merck & Co., Bristol Myers Squibb, Daiichi Sankyo, Takeda, Boehringer Ingelheim, Genmab, Merck Group, Blueprint, Merus, Johnson & Johnson, Hutchmed, Rigel Pharmaceuticals, Taiho Pharmaceutical, Xcovery, Cullinan Therapeutics, Dizal Pharmaceutical.
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
EGFR and HER2 inhibitors
- Approved drugs
- Tagrisso (osimertinib; AstraZeneca)
- Rybrevant (amivantamab-vmjw; Genmab/Johnson & Johnson) and Lazcluze/Leclaza (lazertinib; Johnson & Johnson)
- Pipeline drugs
- Zipalertinib (Cullinan Therapeutics/Taiho Pharmaceutical); Sunvozertinib (Dizal Pharmaceutical); Zongertinib (Boehringer Ingelheim); Zenocutuzumab (Merus)
Antibody-drug conjugates
- Approved drugs
- Enhertu (trastuzumab deruxtecan; Daiichi Sankyo/AstraZeneca)
- Pipeline drugs
- Datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca); Sacituzumab tirumotecan (Merck & Co.); Patritumab deruxtecan (Daiichi Sankyo/Merck & Co.); Telisotuzumab vedotin (AbbVie)
ALK inhibitors
- Approved drugs
- Alecensa (alectinib; Roche); Alunbrig (brigatinib; Takeda); Lorbrena/Lorviqua (lorlatinib; Pfizer); Zykadia (ceritinib; Novartis)
- Pipeline drugs
- Ensartinib (Xcovery)
KRAS inhibitors
- Approved drugs
- Krazati (adagrasib; Bristol Myers Squibb) and Lumakras/Lumykras (sotorasib; Amgen)
- Pipeline drugs
- Olomorasib (Lilly); MK-1084 (Merck & Co.); Divarasib (Roche)
MET inhibitors
- Approved drugs
- Tabrecta (capmatinib; Novartis) and Tepmetko (tepotinib; Merck Group)
- Pipeline drugs
- Savolitinib (AstraZeneca/HUTCHMED)
RET inhibitors
- Approved drugs
- Gavreto (pralsetinib; Rigel Pharmaceuticals/Blueprint Medicines) and Retevmo/Retsevmo (selpercatinib; Lilly)
ROS inhibitors
- Approved drugs
- Augtyro (repotrectinib; Bristol Myers Squibb)
BRAF inhibitors
- Approved drugs
- Braftovi (encorafenib; Pfizer) and Mektovi (binimetinib; Pfizer); Tafinlar (dabrafenib; Novartis) and Mekinist (trametinib; Novartis)
Other mechanisms of action
- Approved drugs
- Xalkori (crizotinib; Pfizer)
Future treatment trends
- Key insights summary
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe
KOL Bulletins
